Cardiff Oncology (CRDF) Stock Price, News & Analysis

Company Overview

Cardiff Oncology, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development. These candidates target pathways implicated in tumor immune evasion, with the goal of inducing immunogenic cell death and improving response rates. The company’s strategic approach emphasizes combination regimens, pairing its agents with established immunotherapies to potentially increase efficacy in solid tumors.

Since its founding in 2015, Cardiff Oncology has pursued strategic collaborations to accelerate its programs, notably entering a research agreement with Merck & Co. to explore combination studies with pembrolizumab. The company conducts its clinical trials across multiple sites in the United States and internationally, serving a global oncology community committed to developing new therapeutic options for patients with cancer.

Key Stats

• Today's Range: $0.93 to $0.97
• 50-Day Range: $0.81 to $1.90
• 52-Week Range: $0.76 to $3.31
• Volume: 446,330 shs
• Average Volume: 1.73 million shs
• Market Capitalization: $65.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Hold

Cardiff Oncology Stock Analysis - MarketRank™

Cardiff Oncology scored higher than 72% of companies evaluated by MarketBeat, and ranked 191st out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Hold

Consensus Rating

Cardiff Oncology has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on no strong buy ratings, 2 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Cardiff Oncology has a consensus price target of $7.50, representing about 680.9% upside from its current price of $0.96.

Amount of Analyst Coverage

Cardiff Oncology has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cardiff Oncology are expected to decrease in the coming year, from ($0.66) to ($0.77) per share.

Price to Book Value per Share Ratio

Cardiff Oncology has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

19.28% of the float of Cardiff Oncology has been sold short.

Short Interest Ratio / Days to Cover

Cardiff Oncology has a short interest ratio ("days to cover") of 6.16.

Change versus previous month

Short interest in Cardiff Oncology has recently decreased by 5.68%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cardiff Oncology does not currently pay a dividend.

Dividend Growth

Cardiff Oncology does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.45

News Sentiment

Cardiff Oncology has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cardiff Oncology this week, compared to 3 articles on an average week.

Search Interest

9 people have searched for CRDF on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

2 people have added Cardiff Oncology to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.1 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Cardiff Oncology in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $66,491.00 in company stock, which represents 0.1011% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Cardiff Oncology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $66,491.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

8.50% of the stock of Cardiff Oncology is held by insiders.

Percentage Held by Institutions

16.29% of the stock of Cardiff Oncology is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CRDF
• CIK: 1213037
• Web: cardiffoncology.com
• Phone: (858) 952-7570
• Fax: N/A
• Employees: 20
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Cardiff Oncology: $7.50
• High Price Target: $12.00
• Low Price Target: $2.00
• Potential Upside/Downside: +680.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.85 million
• Net Margins: -8,527.43%
• Pretax Margin: -8,526.09%
• Return on Equity: -95.51%
• Return on Assets: -71.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.27
• Quick Ratio: 3.27

Sales & Book Value

• Annual Sales: $590 thousand
• Price / Sales: 111.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.67 per share
• Price / Book: 1.43

Miscellaneous

• Outstanding Shares: 68,500,000
• Free Float: 62,679,000
• Market Cap: $65.79 million
• Optionable: Optionable
• Beta: 1.49